Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer

Publisher Website
Google Scholar
Abstract
Thirty-six patients with recurrent carcinoma of the head and neck and no prior exposure to chemotherapy were treated with ifosfamide. This drug was administered, concomitantly with Mesna, as a 24-hr infusion at a dose of 5–6.25 g/m2 every 3 weeks. Objective activity in 32 evaluable patients was 28% (9/32, 95% C.I. 17%-39%); 40% of patients had leukocyte values 3 and 6% platelets 3. Nonhemato-logic toxicity consisted mainly of nausea/vomiting (66% ⩾ grade 2) and alopecia (80% ⩾ grade 2). The activity encountered warrants further studies with this drug in head and neck cancer.

This publication has 2 references indexed in Scilit: